216 related articles for article (PubMed ID: 31718619)
1. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619
[TBL] [Abstract][Full Text] [Related]
2. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry of mammary Paget's disease. Cytokeratin 7, GATA3, and HER2 are sensitive markers.
Arain SA; Arafah M; Said Raddaoui EM; Tulba A; Alkhawaja FH; Al Shedoukhy A
Saudi Med J; 2020 Mar; 41(3):232-237. PubMed ID: 32114594
[TBL] [Abstract][Full Text] [Related]
4. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
5. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance.
Gonzalez RS; Wang J; Kraus T; Sullivan H; Adams AL; Cohen C
Hum Pathol; 2013 Jun; 44(6):1065-70. PubMed ID: 23266442
[TBL] [Abstract][Full Text] [Related]
6. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.
Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A
Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
8. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
9. The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
Yildirim E; Bektas S; Gundogar O; Findik D; Alcicek S; Erdogan KO; Yildiz M
Anticancer Res; 2020 Oct; 40(10):5649-5657. PubMed ID: 32988889
[TBL] [Abstract][Full Text] [Related]
10. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
11. Urothelial tumors with villous morphology: Histomorphology and role of immunohistochemistry in diagnosis.
Mitra S; Chatterjee D; Das A; Gupta K; Radotra BD; Mandal AK
APMIS; 2018 Mar; 126(3):191-200. PubMed ID: 29399882
[TBL] [Abstract][Full Text] [Related]
12. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
13. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
15. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
Braxton DR; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
[TBL] [Abstract][Full Text] [Related]
16. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
17. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.
Afzaljavan F; Sadr AS; Savas S; Pasdar A
Sci Rep; 2021 Jan; 11(1):1679. PubMed ID: 33462316
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis.
Guo Y; Yu P; Liu Z; Maimaiti Y; Chen C; Zhang Y; Yin X; Wang S; Liu C; Huang T
PLoS One; 2017; 12(4):e0174843. PubMed ID: 28394898
[TBL] [Abstract][Full Text] [Related]
19. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
20. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
